Skip to main content

Table 1 Correlation of PDXK expression with different clinicopathological items of 30 patients with HCC in our clinical cohort

From: Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma

 

PDXK Low (N = 17)

PDXK High (N = 13)

P-value

Gender

Female

2 (11.8%)

1 (7.7%)

1

Male

15 (88.2%)

12 (92.3%)

Age (years)

Mean (SD)

47.9 (12.5)

51.6 (7.78)

0.333

Median [Min, Max]

47.0 [30.0, 74.0]

50.0 [40.0, 65.0]

AFP

 < 20

8 (47.1%)

7 (53.8%)

1

 > 20

9 (52.9%)

6 (46.2%)

HBsAg

Mean (SD)

0.765 (0.437)

0.846 (0.376)

0.588

Median [Min, Max]

1.00 [0, 1.00]

1.00 [0, 1.00]

Distant metastases

Mean (SD)

0.118 (0.332)

0.231 (0.439)

0.446

Median [Min, Max]

0 [0, 1.00]

0 [0, 1.00]

Tumor size (cm)

 < 3

5 (29.4%)

2 (15.4%)

0.642

 > 3

12 (70.6%)

11 (84.6%)

Tumor count

Mean (SD)

1.12 (0.485)

1.46 (0.967)

0.257

Median [Min, Max]

1.00 [1.00, 3.00]

1.00 [1.00, 4.00]

PVTT

Mean (SD)

0.118 (0.332)

0.308 (0.480)

0.236

Median [Min, Max]

0 [0, 1.00]

0 [0, 1.00]

Cirrhosis

Mean (SD)

0.529 (0.514)

0.385 (0.506)

0.448

Median [Min, Max]

1.00 [0, 1.00]

0 [0, 1.00]

BCLC stage

A

13 (76.5%)

8 (61.5%)

0.665

B

1 (5.9%)

1 (7.7%)

C

3 (17.6%)

4 (30.8%)

TNM stage

I Stage

9 (52.9%)

5 (38.5%)

0.426

II Stage

4 (23.5%)

2 (15.4%)

III Stage

4 (23.5%)

6 (46.2%)

Tumor grade

2

9 (52.9%)

2 (15.4%)

0.104

3

7 (41.2%)

10 (76.9%)

4

1 (5.9%)

1 (7.7%)

  1. PVTT Portal vein tumor thrombus